Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,320,000 shares, an increase of 12.1% from the December 15th total of 2,070,000 shares. Approximately 20.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 412,100 shares, the short-interest ratio is currently 5.6 days.

Institutional Trading of Jasper Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Jasper Therapeutics in the third quarter worth about $251,000. Samsara BioCapital LLC boosted its stake in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Wellington Management Group LLP bought a new position in shares of Jasper Therapeutics in the third quarter worth approximately $447,000. Ally Bridge Group NY LLC increased its stake in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares during the period. Finally, Braidwell LP bought a new stake in Jasper Therapeutics during the 3rd quarter valued at $9,091,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

NASDAQ JSPR traded up $0.17 during trading hours on Friday, reaching $5.51. 720,615 shares of the stock traded hands, compared to its average volume of 549,720. The stock has a 50 day simple moving average of $19.37 and a two-hundred day simple moving average of $19.60. Jasper Therapeutics has a 1 year low of $5.25 and a 1 year high of $31.01. The company has a market cap of $82.65 million, a price-to-earnings ratio of -1.16 and a beta of 2.18.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. HC Wainwright decreased their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, JMP Securities reissued a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.